Skip header and navigation

Refine By

28 records – page 1 of 3.

The absence of immunoreactivity for tissue inhibitor of metalloproteinase-1 (TIMP-1), but not for TIMP-2, protein is associated with a favorable prognosis in aggressive breast carcinoma.

https://arctichealth.org/en/permalink/ahliterature16897
Source
Oncology. 2005;68(2-3):196-203
Publication Type
Article
Date
2005
Author
Paula Kuvaja
Anne Talvensaari-Mattila
Paavo Pääkkö
Taina Turpeenniemi-Hujanen
Author Affiliation
Department of Oncology and Radiotherapy, Oulu University Hospital, Oulu, Finland.
Source
Oncology. 2005;68(2-3):196-203
Date
2005
Language
English
Publication Type
Article
Keywords
Adult
Aged
Aged, 80 and over
Breast Neoplasms - enzymology - pathology
Carcinoma - enzymology - pathology
Disease Progression
Female
Gene Expression Regulation, Enzymologic
Gene Expression Regulation, Neoplastic
Humans
Immunohistochemistry
Middle Aged
Predictive value of tests
Prognosis
Proportional Hazards Models
Research Support, Non-U.S. Gov't
Survival Analysis
Tissue Inhibitor of Metalloproteinase-1 - analysis - immunology
Tissue Inhibitor of Metalloproteinase-2 - analysis - immunology
Abstract
OBJECTIVES: High tumor grade and lymph node positivity are associated with poor prognosis in breast carcinoma. Prognostic markers are used to define which patient groups benefit from different treatment modalities, some of which are potentially very toxic. Matrix metalloproteinases (MMPs) degrade the extracellular matrix, and type IV collagenases MMP-2 and -9 have been linked to invasive behavior of several malignancies. Tissue inhibitors of metalloproteinases (TIMPs) -1 and -2 inhibit their activity and are therefore considered to have an inhibitory effect on tumor progression. The role of TIMPs in progression of breast carcinoma is, however, still poorly known. Here the effect of TIMP-1 and -2 on survival was examined in lymph node-positive breast carcinoma patients. METHODS: TIMP-1 or -2 was evaluated with avidin-biotin immunohistochemical staining from paraffin-embedded sections of primary breast carcinoma of 132 cases. RESULTS: Positive staining for TIMP-1 and -2 was observed in 81 and 84% of the tumors respectively. TIMP-1 correlated to the grade of the tumor (p = 0.047). Absence of TIMP-1 protein correlated with favorable disease-specific survival of the patients with high-grade tumors. After 10 years of follow-up as high as 88% of patients with a grade 2-3, but TIMP-1-negative tumor were alive, when only 61% of the TIMP-1-positive cases in this group survived by that time (p = 0.03). CONCLUSION: Our results suggest that lack of TIMP-1 protein expression is associated with a favorable prognosis in patients with node-positive high-grade breast carcinoma.
PubMed ID
16006757 View in PubMed
Less detail

Biological roles and prognostic values of the epithelial-mesenchymal transition-mediating transcription factors Twist, ZEB1 and Slug in diffuse large B-cell lymphoma.

https://arctichealth.org/en/permalink/ahliterature118594
Source
Histopathology. 2013 Jan;62(2):326-33
Publication Type
Article
Date
Jan-2013
Author
Siria Lemma
Peeter Karihtala
Kirsi-Maria Haapasaari
Esa Jantunen
Ylermi Soini
Risto Bloigu
Anna-Kaisa Pasanen
Taina Turpeenniemi-Hujanen
Outi Kuittinen
Author Affiliation
Department of Radiotherapy and Oncology, Oulu University Hospital, Oulu, Finland. slemma@mail.student.oulu.fi
Source
Histopathology. 2013 Jan;62(2):326-33
Date
Jan-2013
Language
English
Publication Type
Article
Keywords
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cell Nucleus - metabolism - pathology
Cyclophosphamide - therapeutic use
Doxorubicin - therapeutic use
Epithelial-Mesenchymal Transition
Finland - epidemiology
Homeodomain Proteins - metabolism
Humans
Lymphoma, Large B-Cell, Diffuse - diagnosis - drug therapy - metabolism - mortality
Middle Aged
Neoplasm Staging
Nuclear Proteins - metabolism
Prednisone - therapeutic use
Prognosis
Survival Rate
Transcription Factors - metabolism
Tumor Markers, Biological - metabolism
Twist Transcription Factor - metabolism
Vincristine - therapeutic use
Young Adult
Abstract
To evaluate the biological roles and prognostic significance of the epithelial-mesenchymal transition (EMT)-mediating transcription factors (TFs) Twist, ZEB1 and Slug in patients with diffuse large B-cell lymphoma (DLBCL). EMT has been shown to enhance solid tumour metastasis, invasion, and proliferation.
Expression of Twist, ZEB1 and Slug was evaluated immunohistochemically in eight samples from reactive lymphoid tissues and in diagnostic samples from 102 DLBCL patients treated with curative intent with R-CHOP-type chemotherapy. ZEB1 and Slug expression correlated with adverse disease presentation. However, cytoplasmic Slug expression was linked to a favourable disease outcome, whereas nuclear expression of ZEB1 indicated an adverse outcome.
This study shows that an EMT-like process occurs in lymphomas. Of the TFs investigated, ZEB1 seems to be the main one associated with adverse clinical presentation and clinical outcome. Surprisingly, Slug expression in cytoplasm was linked to a favourable prognosis. Further studies are needed to evaluate whether inhibition of ZEB1 could serve as a therapeutic target.
PubMed ID
23190132 View in PubMed
Less detail

Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study.

https://arctichealth.org/en/permalink/ahliterature131332
Source
Breast Cancer Res. 2011;13(5):R87
Publication Type
Article
Date
2011
Author
Harri Sihto
Johan Lundin
Mikael Lundin
Tiina Lehtimäki
Ari Ristimäki
Kaija Holli
Liisa Sailas
Vesa Kataja
Taina Turpeenniemi-Hujanen
Jorma Isola
Päivi Heikkilä
Heikki Joensuu
Author Affiliation
Laboratory of Molecular Oncology, University of Helsinki, Biomedicum Helsinki, Haartmaninkatu 8, 00290, Helsinki, Finland. harri.sihto@helsinki.fi
Source
Breast Cancer Res. 2011;13(5):R87
Date
2011
Language
English
Publication Type
Article
Keywords
Antigens, CD - metabolism
Bone Neoplasms - metabolism - secondary
Brain Neoplasms - metabolism - secondary
Breast Neoplasms - metabolism - pathology
Cadherins - metabolism
Cohort Studies
Cyclooxygenase 2 - metabolism
Female
Finland
Follow-Up Studies
Glycoproteins - metabolism
Humans
Intermediate Filament Proteins - metabolism
Keratin-5 - metabolism
Liver Neoplasms - metabolism - secondary
Lung Neoplasms - metabolism - secondary
Nerve Tissue Proteins - metabolism
Nestin
Peptides - metabolism
Proteins - analysis - metabolism
Receptor, Epidermal Growth Factor - metabolism
Receptor, erbB-2 - metabolism
Receptors, Estrogen - metabolism
Receptors, Progesterone - metabolism
Skin Neoplasms - metabolism - secondary
Transcription Factors - metabolism
Abstract
Some molecular subtypes of breast cancer have preferential sites of distant relapse. The protein expression pattern of the primary tumor may influence the first distant metastasis site.
We identified from the files of the Finnish Cancer Registry patients diagnosed with breast cancer in five geographical regions Finland in 1991-1992, reviewed the hospital case records, and collected primary tumor tissue. Out of the 2,032 cases identified, 234 developed distant metastases after a median follow-up time of 2.7 years and had the first metastatic site documented (a total of 321 sites). Primary tumor microarray (TMA) cores were analyzed for 17 proteins using immunohistochemistry and for erbB2 using chromogenic in situ hybridization, and their associations with the first metastasis site were examined. The cancers were classified into luminal A, luminal B, HER2+ enriched, basal-like or non-expressor subtypes.
A total of 3,886 TMA cores were analyzed. Luminal A cancers had a propensity to give rise first to bone metastases, HER2-enriched cancers to liver and lung metastases, and basal type cancers to liver and brain metastases. Primary tumors that gave first rise to bone metastases expressed frequently estrogen receptor (ER) and SNAI1 (SNAIL) and rarely COX2 and HER2, tumors with first metastases in the liver expressed infrequently SNAI1, those with lung metastases expressed frequently the epidermal growth factor receptor (EGFR), cytokeratin-5 (CK5) and HER2, and infrequently progesterone receptor (PgR), tumors with early skin metastases expressed infrequently E-cadherin, and breast tumors with first metastases in the brain expressed nestin, prominin-1 and CK5 and infrequently ER and PgR.
Breast tumor biological subtypes have a tendency to give rise to first distant metastases at certain body sites. Several primary tumor proteins were associated with homing of breast cancer cells.
Notes
Cites: Cancer. 2011 May 1;117(9):1837-4621509760
Cites: Clin Cancer Res. 2008 Jul 1;14(13):4103-1018593987
Cites: Cell Tissue Res. 2005 Jan;319(1):15-2615558321
Cites: Lancet. 2005 Feb 19-25;365(9460):671-915721472
Cites: CA Cancer J Clin. 2005 Mar-Apr;55(2):74-10815761078
Cites: Clin Cancer Res. 2005 Aug 15;11(16):5678-8516115903
Cites: Ann Oncol. 2006 Jun;17(6):935-4416603601
Cites: JAMA. 2006 Jun 7;295(21):2492-50216757721
Cites: Oncol Rep. 2006 Jul;16(1):119-2216786133
Cites: Cancer. 2006 Aug 15;107(4):696-70416826579
Cites: J Pathol. 2007 Mar;211(4):481-817294421
Cites: Nature. 2007 Apr 12;446(7137):765-7017429393
Cites: Clin Cancer Res. 2008 Apr 1;14(7):1938-4618381931
Cites: Cancer. 2000 Jan 1;88(1):95-10710618611
Cites: Breast Cancer Res Treat. 2000 Feb;59(3):271-810832597
Cites: J Clin Oncol. 2001 Jan 1;19(1):28-3611134192
Cites: Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-7411553815
Cites: Cancer Res. 2002 Feb 1;62(3):632-511830510
Cites: N Engl J Med. 2002 Dec 19;347(25):1999-200912490681
Cites: Breast Cancer Res Treat. 2003 Mar;78(1):105-1812611463
Cites: Clin Cancer Res. 2003 Mar;9(3):923-3012631589
Cites: Cancer Res. 2008 May 1;68(9):3108-1418451135
Cites: Cancer. 1983 Dec 15;52(12):2349-546640506
Cites: Breast. 2008 Aug;17(4):323-3418455396
Cites: Neurochem Res. 2008 Dec;33(12):2407-1518493853
Cites: Ann Oncol. 2008 Dec;19(12):2012-918641006
Cites: Am J Surg Pathol. 2009 Feb;33(2):163-7518936692
Cites: J Clin Oncol. 2009 Mar 10;27(8):1168-7619204205
Cites: Cancer Metastasis Rev. 2009 Jun;28(1-2):151-6619153669
Cites: Clin Cancer Res. 2009 Jun 1;15(11):3733-919458057
Cites: Eur J Cancer. 2009 Jul;45(11):1916-2319398327
Cites: Ann Oncol. 2009 Sep;20(9):1499-50419299408
Cites: J Clin Oncol. 2009 Nov 1;27(31):5278-8619770385
Cites: Clin Breast Cancer. 2009 Nov;9(4):225-3019933077
Cites: Ann Oncol. 2010 May;21(5):942-819840953
Cites: Hum Pathol. 2010 Jun;41(6):914-720338615
Cites: Ann Oncol. 2010 Jun;21(6):1254-6119858088
Cites: J Clin Oncol. 2010 Jun 1;28(16):2784-9520404251
Cites: J Clin Oncol. 2010 Jul 10;28(20):3271-720498394
Cites: Breast Cancer Res. 2010;12(4):R4620604919
Cites: Nature. 2004 Nov 18;432(7015):396-40115549107
PubMed ID
21914172 View in PubMed
Less detail

Clinicopathological correlations of TIMP-1 and TIMP-2 in Hodgkin's lymphoma.

https://arctichealth.org/en/permalink/ahliterature17921
Source
Eur J Haematol. 2004 Jan;72(1):1-9
Publication Type
Article
Date
Jan-2004
Author
Heli Pennanen
Outi Kuittinen
Ylermi Soini
Taina Turpeenniemi-Hujanen
Author Affiliation
Department of Oncology and Radiotherapy, Oulu University Hospital, Finland.
Source
Eur J Haematol. 2004 Jan;72(1):1-9
Date
Jan-2004
Language
English
Publication Type
Article
Keywords
Adult
Aged
Aged, 80 and over
Connective Tissue - pathology
Female
Hodgkin Disease - classification - drug therapy - mortality - pathology - radiotherapy
Humans
Immunohistochemistry
Male
Middle Aged
Neoplasm Staging
Research Support, Non-U.S. Gov't
Survival Analysis
Time Factors
Tissue Inhibitor of Metalloproteinase-1 - metabolism
Tissue Inhibitor of Metalloproteinase-2 - metabolism
Abstract
OBJECTIVES: The influence of matrix-tumour interactions in Hodgkin's lymphoma is poorly characterised, although a large part of the tumour often consists of reactive tissue. The aim of the present study was to assess the clinicopathological role of two main inhibitors of matrix metalloproteinases, TIMP-1 and TIMP-2, in Hodgkin's lymphoma. MATERIALS AND METHODS: The TIMP-1 and TIMP-2 protein expressions were studied from paraffin-embedded tumour sections of 68 patients with Hodgkin's lymphoma by using immunostaining with TIMP-1 and TIMP-2-specific antibodies. The results of the stainings were compared with the clinicopathological disease characteristics. RESULTS: A total of 33.3% of the tumour tissue sections expressed TIMP-1 and 46.8% expressed TIMP-2. The expression of the TIMP-1 protein was found to be strongly associated with the nodular sclerosis subtype (P = 0.015) and the existence of a bulky tumour (P = 0.004) in Hodgkin's lymphoma. The expression of the TIMP-2 protein, on the other hand, correlated with the occurrence of B symptoms (P = 0.032). CONCLUSIONS: These results provide the first clinical evidence suggesting that TIMP-1 could promote growth of Hodgkin's lymphoma, and may be linked to connective tissue turnover in the nodular sclerosis subtype. However, TIMP-2 is shown to correlate with systemic symptoms.
PubMed ID
14962256 View in PubMed
Less detail

Constant pattern of relapse in primary central nervous lymphoma patients treated with high-dose methotrexate combinations. A Finnish retrospective study.

https://arctichealth.org/en/permalink/ahliterature270036
Source
Acta Oncol. 2015 Jun;54(6):939-43
Publication Type
Article
Date
Jun-2015
Author
Liisa Harjama
Hanne Kuitunen
Taina Turpeenniemi-Hujanen
Kirsi Maria Haapasaari
Sirpa Leppä
Susanna Mannisto
Marja-Liisa Karjalainen-Lindsberg
Tuula Lehtinen
Mine Eray
Martine Vornanen
Hannu Haapasalo
Ylermi Soini
Esa Jantunen
Tapio Nousiainen
Kaija Vasala
Outi Kuittinen
Source
Acta Oncol. 2015 Jun;54(6):939-43
Date
Jun-2015
Language
English
Publication Type
Article
Keywords
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Brain Neoplasms - drug therapy
Cytarabine - administration & dosage
Disease-Free Survival
Female
Finland
Humans
Lymphoma - drug therapy
Male
Methotrexate - administration & dosage
Middle Aged
Recurrence
Retrospective Studies
Rituximab - administration & dosage
Survival Rate
Treatment Outcome
Abstract
Primary central nervous system lymphoma (PCNSL) is a rare brain tumour with a dismal prognosis. Several phase II studies with high-dose methotrexate-based regimens have shown promising early results, but in all hospital-based data published so far, the disease outcome is poor.
We performed a hospital-based retrospective analysis to evaluate the long-term results of the Nordic type of Bonn chemotherapy regimen in PCNSL patients. The study included 54 patients with newly diagnosed PCNSL who received chemotherapy with curative intent as their first-line treatment.
We found promising response rates, 76% of the patients achieving CR and 22% patients achieving PR, with corresponding two-year EFS 53% and OS 76%. However, with longer follow-up a constant pattern of relapses was observed with only one patient remaining in primary remission after 60 months.
The finding suggests that basic biological differences exist between PCNSL and systemic diffuse large B-cell lymphoma and there is a need for consolidation or maintenance therapy after achieving a remission in patients with PCNSL.
PubMed ID
25761092 View in PubMed
Less detail

Diverse role of MMP-2 and MMP-9 in the clinicopathological behavior of Hodgkin's lymphoma.

https://arctichealth.org/en/permalink/ahliterature18799
Source
Eur J Haematol. 2002 Oct;69(4):205-12
Publication Type
Article
Date
Oct-2002
Author
Outi Kuittinen
Ylermi Soini
Taina Turpeenniemi-Hujanen
Author Affiliation
Department of Oncology and Radiotherapy, Oulu University Hospital, Kajaanintie 50, 90220 Oulu, Finland.
Source
Eur J Haematol. 2002 Oct;69(4):205-12
Date
Oct-2002
Language
English
Publication Type
Article
Keywords
Gelatinase A - biosynthesis
Gelatinase B - biosynthesis
Hodgkin Disease - enzymology - pathology - physiopathology
Humans
Immunohistochemistry
Lymphocytes - enzymology
Prognosis
Reed-Sternberg Cells - enzymology
Research Support, Non-U.S. Gov't
Survival Analysis
Tumor Markers, Biological
Abstract
This is the first study to describe the role of MMP-2 and MMP-9 in Hodgkin's disease. Strong MMP-2 expression correlated with a favorable prognosis, while MMP-9 expression showed a tendency toward an adverse outcome. MMP-9 expression correlated with B symptoms and decreased new vessel formation. MMP-2 expression was associated with the nodular sclerosis subtype, and its expression was most pronounced in the vicinity of sclerosis. Neither of the gelatinases nor the extent of neovascularization correlated with tumor stage, the occurrence of bulky disease, or extranodal infiltrates. Together, these findings imply that the adverse role of MMP-9 may be associated with the controlling of immunological processes but not the invasion probabilities or neovascularization of the tumor. The favorable prognostic value of MMP-2 is surprising in view of the role of MMPs in solid tumors. This, however, may be linked to the basic biological differences of hematological malignancies vs. other tumors.
PubMed ID
12431239 View in PubMed
Less detail

Expression of matrix metalloproteinase-9 in head and neck squamous cell carcinoma: a potential marker for prognosis.

https://arctichealth.org/en/permalink/ahliterature17724
Source
Clin Cancer Res. 2004 May 1;10(9):3110-6
Publication Type
Article
Date
May-1-2004
Author
Henni Ruokolainen
Paavo Pääkkö
Taina Turpeenniemi-Hujanen
Author Affiliation
Department of Oncology and Radiotherapy, Oulu University Hospital, Oulu, Finland.
Source
Clin Cancer Res. 2004 May 1;10(9):3110-6
Date
May-1-2004
Language
English
Publication Type
Article
Keywords
Adult
Aged
Aged, 80 and over
Carcinoma, Squamous Cell - enzymology - pathology
Female
Gelatinase B - biosynthesis
Head and Neck Neoplasms - enzymology - pathology
Humans
Immunohistochemistry
Male
Middle Aged
Neoplasm Staging
Prognosis
Research Support, Non-U.S. Gov't
Sex Factors
Survival Analysis
Tumor Markers, Biological - biosynthesis
Abstract
PURPOSE: Previous studies have shown that matrix metalloproteinase-9 (MMP-9) is expressed in malignant head and neck squamous cell carcinoma. The prognostic role of MMP-9 is still unclear. The aim of this study was to investigate the role of MMP-9 immunoreactive protein as a prognostic marker for survival in head and neck squamous cell carcinoma. EXPERIMENTAL DESIGN: Overexpression of the immunoreactive protein for MMP-9 was evaluated in tissue sections of 74 primary head and neck carcinomas with a monoclonal antibody using a biotin-streptavidin immunohistochemical staining method. The staining results were compared with the clinical data and to the patients' outcome. RESULTS: Positive immunostaining for MMP-9 was observed in 82% of the head and neck carcinomas, 39% of the cases being extensively positive. MMP-9 protein expression was independent of the stage or the grade of the tumor. The expression of MMP-9 was prognostic for shortened survival, the 5-year cause-specific survival being 45% in MMP-9 positive cases, and 92% in cases negative for MMP-9 (P = 0.013). MMP-9 positivity also correlated to the relapse-free survival (P = 0.019). At the 5-year follow-up, the cumulative relapse-free survival rate was 79% for patients with MMP-9-negative tumor and 42% for the patients with positive immunostaining for MMP-9. High expression of MMP-9 seemed to be linked with more aggressive relapses, appearing in 33% of the cases in local relapses, in 52% of cases with lymph node relapses, and in 60% of the cases with hematogenic relapses. CONCLUSIONS: This is the first study with a long follow-up showing that the immunoreactive protein of MMP-9 in head and neck carcinoma is associated with shortened relapse-free and cause-specific survival, suggesting that MMP-9 has a role in tumor progression of head and neck carcinomas, as well as in estimation of the prognosis of these diseases.
PubMed ID
15131051 View in PubMed
Less detail

Front-line bevacizumab in serous epithelial ovarian cancer: biomarker analysis of the FINAVAST trial.

https://arctichealth.org/en/permalink/ahliterature97346
Source
Anticancer Res. 2010 Mar;30(3):1001-6
Publication Type
Article
Date
Mar-2010
Author
Peeter Karihtala
Johanna Mäenpää
Taina Turpeenniemi-Hujanen
Ulla Puistola
Author Affiliation
Department of Oncology and Radiotherapy, P.O. Box 22, FIN-90029 Oulu University Hospital, Finland. peeter.karihtala@oulu.fi.
Source
Anticancer Res. 2010 Mar;30(3):1001-6
Date
Mar-2010
Language
English
Publication Type
Article
Keywords
Aged
Antibodies, Monoclonal - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carboplatin - administration & dosage
Female
Guanine - analogs & derivatives - blood - metabolism
Humans
Hypoxia-Inducible Factor 1, alpha Subunit - blood - metabolism
Immunohistochemistry
Matrix Metalloproteinase 2 - blood - metabolism
Matrix Metalloproteinase 9 - blood - metabolism
Middle Aged
Ovarian Neoplasms - blood - drug therapy - metabolism - surgery
Paclitaxel - administration & dosage
Receptors, Vascular Endothelial Growth Factor - blood - metabolism
Tissue Inhibitor of Metalloproteinase-1 - blood - metabolism
Tumor Markers, Biological - blood - metabolism
Vascular Endothelial Growth Factor A - blood - metabolism
Abstract
BACKGROUND: Potential tissue and serum biomarkers were assessed for predicting efficacy of bevacizumab in ovarian cancer (OC). PATIENTS AND METHODS: Twenty patients with OC received chemotherapy alone (control group) or in combination with bevacizumab (study group) in this non-randomised study. Pre- and post-treatment serum concentrations of vascular endothelial growth factor (VEGF), 8-hydroxydeoxyguanosine (8-OHdG) and tissue inhibitor of metalloproteinase-1 (TIMP-1) were measured in all patients. In addition, immunohistochemical expressions VEGF receptors (R1, R2), hypoxia-inducible factor 1alpha (HIF-1 alpha), matrix metalloproteinases (-2, -9) and TIMP-2 were analysed in tumours from bevacizumab-treated patients. RESULTS: 8-OHdG and HIF-1alpha immunostainings were more highly expressed among patients with progression-free survival (PFS) >23 months than in patients with PFS
PubMed ID
20393027 View in PubMed
Less detail

Gelatinases A and B (MMP-2 and MMP-9) in endometrial cancer-MMP-9 correlates to the grade and the stage.

https://arctichealth.org/en/permalink/ahliterature178544
Source
Gynecol Oncol. 2004 Sep;94(3):699-704
Publication Type
Article
Date
Sep-2004
Author
Kristina Aglund
Marita Rauvala
Ulla Puistola
Tord Angström
Taina Turpeenniemi-Hujanen
Björn Zackrisson
Ulf Stendahl
Author Affiliation
Department of Oncology, The University of Umeå, Sweden.
Source
Gynecol Oncol. 2004 Sep;94(3):699-704
Date
Sep-2004
Language
English
Publication Type
Article
Keywords
Endometrial Neoplasms - enzymology - pathology
Female
Humans
Immunohistochemistry
Matrix Metalloproteinase 2 - metabolism
Matrix Metalloproteinase 9 - metabolism
Neoplasm Staging
Paraffin Embedding
Predictive value of tests
Prognosis
Survival Rate
Abstract
Matrix metalloproteinases (MMPs) have been linked to aggressive behavior in several malignancies. Gelatinases (MMP-2 and MMP-9) in particular are prognostic factors in many adeno- and epithelial cancers. However, no conclusive data exist concerning the role of gelatinases in endometrial cancer.
Eighty-eight patients with endometrial cancer, treated between 1988 and 1993 in Umeå University Hospital, were included. MMP-2 and MMP-9 proteins were analyzed immunohistochemically from paraffin-embedded tissues by using specific monoclonal antibodies. The staining results were compared to the clinical data.
Fifty-two percent of the cases were positive for MMP-9 and 72% for MMP-2. The overexpression of the proteins of either MMP-2 or MMP-9 was associated with poor survival. The predictive value of MMP-2 expression was most distinct in stage I cancers. An association was found between the positivity of MMP-2 and MMP-9. Only 3% of the cases were highly positive for both gelatinases and 18% of the cases were negative for both MMPs. Both gelatinases correlated to the histological grade. MMP-9 also correlated to the clinical stage of the disease, whereas MMP-2 did not. There was no apparent association with either depth of invasion, menopausal status, or the age of the patient.
MMP-2 and MMP-9 could serve as markers for the clinical behavior of endometrial cancer. They may further be linked to a tendency to cancer relapse. Thus, these gelatinases may turn out to be potentially useful in decision making about the need for an adjuvant treatment.
PubMed ID
15350361 View in PubMed
Less detail

Gelatinases (MMP-2 and MMP-9), TIMP-1 expression and the extent of neovascularization in aggressive non-Hodgkin's lymphomas.

https://arctichealth.org/en/permalink/ahliterature18274
Source
Eur J Haematol. 2003 Aug;71(2):91-9
Publication Type
Article
Date
Aug-2003
Author
Outi Kuittinen
Meeri Apaja-Sarkkinen
Taina Turpeenniemi-Hujanen
Author Affiliation
Department of Oncology and Radiotherapy, Oulu University Hospital, Oulu, Finland.
Source
Eur J Haematol. 2003 Aug;71(2):91-9
Date
Aug-2003
Language
English
Publication Type
Article
Keywords
Biological Markers - analysis
Collagenases - analysis
Disease Progression
Factor VIII - analysis
Gelatinase A - analysis
Gelatinase B - analysis
Humans
Immunohistochemistry
Lymphoma, Non-Hodgkin - diagnosis - enzymology - mortality
Neovascularization, Pathologic - diagnosis - enzymology
Prognosis
Research Support, Non-U.S. Gov't
Survival Analysis
Tissue Inhibitor of Metalloproteinase-1 - analysis
Abstract
OBJECTIVES: The present study was carried out to clarify the role of matrix metalloproteinase-2 and -9 (MMP-2 and MMP-9), tissue inhibitor of metalloproteinase-1 (TIMP-1) and the extent of neovascularization in the clinicopathologic behavior of non-Hodgkin's lymphomas. METHODS: Paraffin-embedded histologic sections from 57 patients with aggressive non-Hodgkin's lymphomas were stained with MMP-2, MMP-9, TIMP-1, and factor VIII antibodies to correlate the expression of these markers to the clinical disease characteristics. RESULTS: Strong MMP-9 staining was found to be an adverse prognostic factor among patients with aggressive B-cell lymphomas, the probabilities for 5-yr disease-free survival being 73%, 63%, 50%, and 0% in patients with grades 0, 1, 2, and 3 staining, respectively. Among the patients with strong (grades 2 and 3) MMP-9 staining, however, positivity for TIMP-1 indicated a trend toward a more favorable prognosis. TIMP-1 expression also correlated with the immunoblastic and anaplastic lymphoma subtypes. The expression of the proteins for MMP-2 and factor VIII had no independent prognostic role. None of the study parameters correlated with disease stage, the occurrence of extranodal infiltrates, the occurrence of bulky tumor, or the IPI scores. CONCLUSIONS: Positivity for MMP-9 immunoreactive protein is an independent sign of an unfavorable prognosis in non-Hodgkin's lymphomas. This is not mediated through influences in tumor dissemination or neovascularization indicating it to carry other important biological functions.
PubMed ID
12890147 View in PubMed
Less detail

28 records – page 1 of 3.